The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, shares findings from a Phase I/II trial (NCT04186520), which utilized adaptive manufacturing of dual-targeted anti-CD19/anti-CD20 CAR T-cells for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL). The regimen demonstrated impressive efficacy and safety, with a best overall response (BOR) rate of 100% in all 17 patients and no instances of high-grade cytokine release syndrome (CRS). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Miltenyi Biotec, TG therapeutic, Umoja, Novartis, Janssen, Epizyme, LOXO-Lilly, BMS/Juno, Seattle Genetics, Gilead/Kite, Incyte, Abbvie, Lilly Oncology
Travel support: Miltenyi Biotec, LOXO-Lilly
Research Funding: Miltenyi Biotec, Lilly Oncology
Current holder of stock options: Tundra Therapeutics
